Journal article icon

Journal article

Empagliflozin in patients with chronic kidney disease

Abstract:

Background

The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.

Methods

We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m2 of body-s... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/NEJMoa2204233

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
ORCID:
0000-0003-1172-8243

Contributors

Publisher:
Massachusetts Medical Society
Journal:
New England Journal of Medicine More from this journal
Volume:
388
Issue:
2
Pages:
117-127
Publication date:
2022-11-04
Acceptance date:
2022-10-20
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Language:
English
Keywords:
Pubs id:
1286417
Local pid:
pubs:1286417
Deposit date:
2022-10-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP